Asante Solutions
Developer of connected diabetes management solutions for people who require insulin. The company designed a prescription, subscription-based system that integrates continuous glucose monitor data, reusable connected insulin pen caps, a mobile application and a cloud clinician portal to provide real-time insulin dose recommendations, remote clinician workflows, patient training and support. Bigfoot has collected and published real-world evidence, pursued regulatory clearances (including FDA 510(k)), acquired algorithmic and device intellectual property, and established commercial partnerships. The company was acquired by Abbott (announced Sept 2023).
Industries
Nr. of Employees
medium (51-250)
Asante Solutions
Patents
Products
Connected insulin pen caps (rapid-acting and long-acting)
Reusable smart pen caps that mount on disposable insulin pens to record dose times, display clinician-prescribed dosing recommendations, show time-since-last-dose, and interact with continuous glucose sensors for current glucose and trend inputs.
Mobile application (patient-facing)
Prescription mobile app that aggregates glucose and dosing data, displays alerts, stores patient history, allows downloading and sharing of formatted reports (e.g., 14-day PDF), and receives clinician-prescribed settings.
Connected blood glucose meter (optional)
Companion blood glucose meter used for fingerstick measurements that can share values with the pen cap and mobile app to support treatment decisions when CGM data is unavailable or confirmation is needed.
Continuous glucose monitoring sensor integration (14-day wear)
Use of a 14-day-wear continuous glucose monitoring sensor integrated into the dosing workflow for continuous glucose and hypoglycemia alerting; sensor data are used by the pen cap and app to inform dose recommendations and alerts.
Connected insulin pen caps (rapid-acting and long-acting)
Reusable smart pen caps that mount on disposable insulin pens to record dose times, display clinician-prescribed dosing recommendations, show time-since-last-dose, and interact with continuous glucose sensors for current glucose and trend inputs.
Mobile application (patient-facing)
Prescription mobile app that aggregates glucose and dosing data, displays alerts, stores patient history, allows downloading and sharing of formatted reports (e.g., 14-day PDF), and receives clinician-prescribed settings.
Connected blood glucose meter (optional)
Companion blood glucose meter used for fingerstick measurements that can share values with the pen cap and mobile app to support treatment decisions when CGM data is unavailable or confirmation is needed.
Continuous glucose monitoring sensor integration (14-day wear)
Use of a 14-day-wear continuous glucose monitoring sensor integrated into the dosing workflow for continuous glucose and hypoglycemia alerting; sensor data are used by the pen cap and app to inform dose recommendations and alerts.
Services
Bundled delivery of connected devices, mobile application, data services and clinician-facing portal provided under a prescription subscription model to support people on multiple daily injections.
Cloud-based portal enabling healthcare professionals to review patient glucose and insulin timing data, configure therapy settings remotely, view AGP reports, and support RPM documentation and clinic workflows.
Support for system setup, device pairing, troubleshooting and user questions via in-app help, phone support and remote training sessions.
Structured onboarding and ongoing education delivered by certified diabetes educators and clinicians using multimodal training materials, simulators and live remote coaching to support safe and effective device use.
Bundled delivery of connected devices, mobile application, data services and clinician-facing portal provided under a prescription subscription model to support people on multiple daily injections.
Cloud-based portal enabling healthcare professionals to review patient glucose and insulin timing data, configure therapy settings remotely, view AGP reports, and support RPM documentation and clinic workflows.
Support for system setup, device pairing, troubleshooting and user questions via in-app help, phone support and remote training sessions.
Structured onboarding and ongoing education delivered by certified diabetes educators and clinicians using multimodal training materials, simulators and live remote coaching to support safe and effective device use.
Expertise Areas
- Connected insulin delivery systems for multiple daily injections (MDI)
- Digital health platforms and mobile application development
- Continuous glucose monitoring integration
- Algorithm development for insulin titration and dose recommendations
Key Technologies
- Continuous glucose monitoring (CGM) integration
- Connected pen-cap hardware and dose-event capture
- Mobile health applications (iOS and Android) and notification management
- Cloud-based clinician portals and remote monitoring platforms
News & Updates
Announcement of definitive agreement for acquisition to combine CGM and insulin injection support capabilities; transaction announced Sept 5, 2023.
Press release announcing completion of the acquisition.
Publication and retrospective analysis reporting potential rapid and durable glycemic improvements from a cohort using the system; published/announced June 21, 2023.
Announcement of acquisition of a reinforcement learning algorithm developed at an academic institution for insulin titration recommendations.
Announcement that the Android version of the patient mobile app received FDA 510(k) clearance (March 2, 2023).
Announcement that the connected insulin management system received FDA 510(k) clearance (May 10, 2021).
Announcement of definitive agreement for acquisition to combine CGM and insulin injection support capabilities; transaction announced Sept 5, 2023.
Press release announcing completion of the acquisition.
Publication and retrospective analysis reporting potential rapid and durable glycemic improvements from a cohort using the system; published/announced June 21, 2023.
Announcement of acquisition of a reinforcement learning algorithm developed at an academic institution for insulin titration recommendations.
Announcement that the Android version of the patient mobile app received FDA 510(k) clearance (March 2, 2023).
Announcement that the connected insulin management system received FDA 510(k) clearance (May 10, 2021).